Insmed (INSM) News Today

Insmed, Inc. (NASDAQ:INSM) shares moved higher as investors digested a flurry of analyst upgrades and price-target hikes, alongside renewed coverage, which helped offset insider stock sales by the CEO, COO and a director.

• Positive Sentiment: JPMorgan Chase & Co. boosted its price target on INSM from $111.00 to $135.00 and kept an overweight rating.Insmed (NASDAQ:INSM) Price Target Raised to $135.00
• Positive Sentiment: Morgan Stanley raised its price target on INSM from $126.00 to $144.00 with an equal weight rating.Insmed price target raised to $144 from $126 at Morgan Stanley
• Positive Sentiment: William Blair initiated coverage on INSM with an outperform rating.Insmed (NASDAQ:INSM) Now Covered by Analysts at William Blair
• Positive Sentiment: Sixteen brokerages maintain a consensus “moderate buy” on INSM.Insmed, Inc. (NASDAQ:INSM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
• Positive Sentiment: JPMorgan Chase issued an additional upbeat forecast for INSM’s stock price.JPMorgan Chase & Co. Issues Positive Forecast for Insmed (NASDAQ:INSM) Stock Price
• Neutral Sentiment: William Blair released detailed EPS estimates for Q3/Q4 2025 and FY 2025–2028, projecting a path back to profitability by FY 2027.Free Report
• Neutral Sentiment: Insmed announced presentations at the Wells Fargo 2025 Healthcare Conference on September 5.Insmed To Present at September Investor Conferences
• Neutral Sentiment: A Benzinga analysis shows what $1,000 invested in Insmed ten years ago would be worth today.$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
• Negative Sentiment: Director Melvin Md Sharoky sold 10,000 shares of INSM.Insmed (NASDAQ:INSM) Director Melvin Md Sharoky Sells 10,000 Shares
• Negative Sentiment: COO Roger Adsett sold 25,000 shares, trimming his stake.SEC Filing
• Negative Sentiment: CEO William Lewis sold 6,865 shares for roughly $881,466, reducing his position by 2.85%.Insmed (NASDAQ:INSM) CEO Sells $881,466.00 in Stock